Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer by E. Orlandi et al.
 Radiochemotherapy and no chemoradiotherapy in OPC 
1 
 
Title: Predictors of patient-reported dysphagia following IMRT plus chemotherapy in 
oropharyngeal cancer 
Running title: radiochemotherapy and no chemoradiotherapy in OPC 
 
Authors: Orlandi E1, Miceli R2, Infante G2, Mirabile A3, Alterio D4, Cossu Rocca M5, Denaro N6, 
Vigna-Taglianti R7, Merlotti A7, Schindler A8, Pizzorni N8, Fallai C9, Licitra L3, Bossi P3 
 
Affiliations: 
1 Radiotherapy 2 Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian, 1, 
20133, Milan, MI, Italy. ester.orlandi@istitutotumori.mi.it. 
2 Unit of Medical Statistics, Biometry and Bioinformatics, Fondazione IRCCS Istituto Nazionale dei 
Tumori, Milan, Italy. 
3 Medical Oncology 3 Department, Fondazione IRCCS Istituto Nazionale dei Tumori, University of 
Milan, Milan, Italy. 
4 Department of Radiotherapy, Advanced Radiotherapy Center, European Institute of Oncology, 
Milan, Italy. 
5 Medical Oncology Division of Urogenital and Head and Neck Tumours, European Institute of 
Oncology, Milan, Italy. 
6 Department of Oncology, Azienda Ospedaliera Santa Croce e Carle, Cuneo, Italy. 
7 Department of Radiation Oncology, Azienda Ospedaliera Santa Croce and Carle, Cuneo, Italy. 
8 Phoniatric Unit, Department of Biomedical and Clinical Sciences, Ospedale Sacco, University of 
Milan, Milan, Italy. 
9 Radiotherapy 2 Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian, 1, 
20133, Milan, MI, Italy. 
 Radiochemotherapy and no chemoradiotherapy in OPC 
2 
 
 
Abstract 
Objective: The aim of this cross-sectional study is to evaluate the factors associated with patient-
reported dysphagia in patients affected by locally-advanced oropharyngeal cancer (OPC) treated 
with definitive intensity modulated radiation therapy (IMRT) and concurrent chemotherapy (CHT), 
with or without induction CHT. 
Methods: We evaluated 148 OPC patients treated with IMRT and concurrent CHT, without 
evidence of disease and who had completed their treatment since at least 6 months. At their 
planned follow-up visit, patients underwent clinical evaluation and completed the M.D. Anderson 
Dysphagia Inventory (MDADI) questionnaire. The association between questionnaire composite 
score (MDADI-CS) and different patients’ and tumor’s characteristics and treatments (covariates) 
was investigated by univariable and multivariable analyses, the latter including only covariates 
significant at univariable analysis.  
Results: With a median time from treatment end of 30 months [range 6-74 months, interquartile 
range (IQR): 16-50 months], the median (IQR) MDADI-CS was 72 (63-84). The majority of patients 
(82.4%) had a MDADI-CS≥60. At multivariable  analysis, female gender, Human Papilloma Virus 
(HPV) negative status, moderate and severe clinician-rated xerostomia were significantly 
associated with lower MDADI-CS.  
Conclusion: Patient-perceived dysphagia was satisfactory or acceptable in the majority of patients. 
HPV status and xerostomia were confirmed as important predictive factors for swallowing 
dysfunction after radiochemotherapy. Data regarding female gender are new and deserve further 
investigation.  
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Introduction 
Long-term dysphagia is reported in 30–50% of head and neck cancer (HNC) patients treated with 
intensive radiochemotherapy (RT-CHT) [1-3]. Although some patients completely respond to 
treatment, up to 50% do not report any improvement after radiotherapy (RT) and continue 
experiencing dysphagia-associated symptoms [4]. Despite the introduction of modern RT 
approaches, e.g. Intensity Modulated Radiation Therapy (IMRT), swallowing dysfunction has 
become the major determinant of quality of life (QoL), potentially superior to xerostomia [4-8]. 
Over the last decades, significant efforts have been devoted to prevent, predict, and ameliorate 
swallowing adverse effects resulting from RT. 
Some treatment-related predictors of dysphagia after definitive IMRT, such as RT mean dose to 
the pharyngeal constrictors muscles, have been investigated [9,10]. Conversely, scant data exist on 
the impact of different clinical and biological characteristics of patients, such as Human Papilloma 
Virus (HPV) status, on the development of dysphagia. Tumor p16 expression, a surrogate marker 
of HPV infection, is a predictor of better baseline and post-treatment overall QoL, compared with 
p16-negative status and regardless of primary treatment modality [11]. Over the last years, many 
studies in HNC patients included the assessment of adverse events through patient reported 
outcome (PRO) measures, providing invaluable information about QoL [12-14]. 
At present, tools that measure patient-rated swallowing outcomes are considered easy to 
administer and sensitive to swallowing changes, especially when non-surgical strategies are 
applied [15]. Among them, the M.D. Anderson Dysphagia Inventory (MDADI) is a practical, disease-
specific and short tool, which has been extensively adopted and so far selected as the primary 
swallowing-related PRO in several ongoing prospective trials [16].  
The main objectives of this study were to examine, in an exploratory fashion, the role of different 
biological and clinical factors, including HPV positivity and physician-reported xerostomia and 
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dysphagia grade, in predicting long-term dysphagia through MDADI in a population of OPC 
patients treated with curative IMRT and concomitant CHT. 
 
Patients and Methods  
We considered consecutive OPC patients treated at three Italian tertiary cancer Centers: National 
Cancer Institute in Milan (INT), European Institute of Oncology in Milan (IEO), and Santa Croce and 
Carle Hospital in Cuneo (Cuneo). This study was approved by each Institutional Scientific and 
Ethical Committee and patients’ informed consent was obtained from all participants. The study 
included patients with stage III-IV A-B OPC (according to VII AJCC staging system [17]) who: (i) had 
received conventional, extended-field IMRT or Volumetric Modulated Arc Therapy (VMAT) (total 
dose of 70 Gy with conventional fractionation, 2-2.12 Gy per fraction), swallowing sparing when 
clinically feasible and concomitant platinum-based chemotherapy (CHT) at least 6 months before 
inclusion, and (ii) with disease in complete remission. Induction CHT (i-CHT) with platinum, 
docetaxel and 5-fluorouracil (TPF) and/or unilateral neck node dissection before or after 
treatment were allowed. Patients who had undergone RT to the head and neck area other than 
OPC curative treatment, patients subjected to total laryngectomy, and those with a concurrent 
neurological disease were excluded. Percutaneous gastrostomy (PEG) was accepted if 
prophylactically placed before starting therapy. As per institutional policies, PEG was not placed in 
a reactive way but enteral nutrition was applied with nasogastric tube (NGT) during treatment as 
needed. 
Data collection 
All the enrolled patients filled in the MDADI questionnaire at planned follow-up visits. Briefly, the 
MDADI consists of a self-reported questionnaire with 20 questions and 4 subscales about 
swallowing-related QoL: Global assessment, single item-MDADI-G; Functional, 5 items-MDADI-F; 
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Physical, 8 items-MDADI-P; and Emotional, 6 items-MDADI-E. Each question includes a 5-point 
response scale. A composite score (MDADI-CS) based on 19 items (excluding the global 
assessment item) was applied to evaluate swallowing-specific QoL. All subscale MDADI scores and 
CSs were normalized to values ranging from 20 (extremely low-functioning) to 100 (high-
functioning) [18]. Higher scores represent better QoL. The Italian version of MDADI has been 
previously validated [19]. As reported also by Goepfert et al. [16], a MDADI-CS of at least 80 
represented “optimal” patient-reported swallowing function, between 60 and 80 was “adequate,” 
and less than 60 was “poor”.  
Xerostomia and dysphagia, as well as other toxicities, were collected by the physician according to 
the Common Terminology Criteria for Adverse Events (CTCAE) v4.0 [20] at the routine follow-up 
visit (at least 6 months after treatment completion); we defined this assessment as “late”. The 
following data were collected: pre-therapy HPV status, time from treatment end, chemotherapy 
timing, neck dissection (before or after treatment), duration of enteral feeding [nasogastric tube 
(NGT) or PEG], RT technique, RT overall treatment time (OTT), and interruptions due to toxicity. 
Baseline physician-reported dysphagia, as well as xerostomia and dysphagia measured during the 
routine follow-up visit, were also recorded. Xerostomia was not considered at baseline because it 
is not expected to be present at this time point. 
Statistical Analysis  
The association between categorical variables was tested using the Fisher-Freeman-Halton test 
[21]. We recorded the MDADI-CS and scores of all subscales for all the patients. The MDADI-CS 
was selected as primary endpoint, as suggested by other Authors [15,22]. The association between 
MDADI-CS and subscales and the following covariates was analyzed: patient’ gender and age, T 
and N stage, previous surgery, treatment strategy (with or without i-CHT), HPV status, dysphagia 
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CTCAE grade (at baseline and at follow-up), xerostomia CTCAE grade, enteral nutrition 
duration/administration, and time from treatment end.  
We used the quartiles (1st, Median and 3rd) to summarize MDADI distributions according to the 
above covariates and the Anderson and Darling (AD) test [23] to test between groups differences 
(univariable analysis). Multivariable analysis was performed only for MDADI-CS using a quantile 
regression model, [24] which included only the covariates achieving 5% significance at univariable 
analysis. The quantile model was applied because it is semiparametric and avoids assumptions 
about the parametric distribution of dependent variable error. Therefore, when the response is 
not a Gaussian variable, such as in the case of MDADI score, it presents advantages compared with 
least squares regression. The model allows estimating and testing groups differences between the 
quantiles of response variable; we chose to model the three MDADI quartiles (median, 1st and 3rd 
quartiles).   
Since our analysis had an exploratory intent, xerostomia and physician-assessed dysphagia grades 
(0, 1, 2) were modeled as linear covariates and the corresponding regression coefficient estimated 
the difference between the MDADI quartiles for every 1-unit increment of the covariate (i.e. G1 vs 
G0 or G2 vs G1). The model results were shown in terms of quartile differences, together with the 
corresponding p-value at Wald test and, only for the significant covariates, we also graphically 
represented the quartile differences and their 95% confidence intervals (CI); CIs not including zero 
correspond to 5% significant differences. 
The analyses were performed with SAS (Cary, NC, USA) and R software [25].  
 
Results 
Overall, 148 patients were enrolled, 101 (68%) at INT, 36 (24%) at IEO and 11 (8%) at Cuneo. 
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Patient and treatment characteristics are shown in Table 1. Seventy-two (48.7%) patients received 
conventional IMRT (step-and-shoot or sliding window techniques) and 76 patients (51.3%) 
received VMAT. Median OTT was 49 days (range 47-55 days). All patients received treatment as 
planned without interruptions due to toxicities. 
Treatment consisted of i-CHT followed by RT-CHT in 54 patients (36%), and concomitant platinum 
based RT-CHT in 94 patients (64%). Median number of i-CHT cycles was 3, and concurrent cisplatin 
was administered on a 3-week schedule in most cases (80%). Eight patients received unilateral 
neck dissection before RT, while 12 patients underwent salvage neck surgery after RT. 
PEG was placed in 6 patients (4%) before the initiation of treatment, as it was prophylactically 
suggested due to the foreseen mucosal toxicity; two of them had it removed immediately at the 
end of the treatment. The other four maintained it to support a moderately-altered swallowing 
function and they removed it from 7 to 30 months from treatment end. No patient received 
reactive PEG during treatment. No patient had PEG in place at the time of the clinical evaluation 
and questionnaires completion. Excluding patients with prophylactic PEG, 47 out of 142 patients 
(33%) had enteral nutrition via NGT during treatment. When performed, median duration of 
enteral feeding was 37 days (interquartile range, IQR, 30-59 days).  
Median time from treatment end was 30 months (range 6-74 months; IQR: 16-50 months), with 61 
patients (41%) having a follow-up of 6 to 24 months, and 87 (59%) with more than 24 months from 
treatment end.  
At the time of the clinical evaluation and questionnaires completion, 109 (74%) patients had grade 
0 dysphagia, 33 (22%) had grade 1, and 6 (4%) patients had grade 2 dysphagia. As for xerostomia, 
47 (32%), 64 (44%) and 36 (24%) patients had grade 0, grade 1 and grade 2 respectively. No 
patient showed mucositis.  
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The median (IQR) scores of MDADI-CS and G, F, P and E subscales were 72 (63-84), 80 (60-80), 80 
(68-92), 73 (67-84), 70 (58-80), respectively. Twenty-six patients had a composite score <60 
(17.6%), and 82.4% had a MDADI-CS ≥ 60. At univariable analysis by Anderson and Darling test, 
MDADI-CS and the subscales were not significantly associated with age, T and N stage, previous 
surgery, treatment strategy and baseline dysphagia grade (data not shown). Moreover, in the T1-2 
subset the HPV negative and positive patients had similar MDADI-CS distribution: the median (IQR) 
was 72 (61-76) vs 72.5 (64.5-88.25) (p =0.110). On the contrary, in the T3-4 subset the HPV 
negative patients had significantly lower MDADI-CS: 64 (56-84) vs 76 (70.3-82.8) (p =0.019).  
Table 2 shows the variables significantly associated with at least one MDADI subscale at 
univariable analysis. Males had significantly higher scores compared with females, both in the CS 
and in all the subscales. HPV positivity was associated with significantly higher scores compared 
with negative status in all the subscales except for MDADI-G. An inverse relationship was observed 
between xerostomia and MDADI score: higher grades were associated with significantly lower 
scores in the CS and in all the subscales. A similar trend was observed for physician-assessed 
dysphagia, but it reached significance only for MDADI-F, MDADI-P and MDADI-CS. Time from 
treatment end >24 months was associated with significantly higher MDADI-F, MDADI-P and 
MDADI-C scores compared with treatment time ≤24 months. The variables significantly associated 
with MDADI-CS at univariable analysis were investigated in a multivariable model; enteral 
nutrition administration was not analyzed because it was associated with significantly lower 
MDADI-F and MDADI-P scores, but significance was not reached for MDADI-CS (p=0.0673; Table 
2). The multivariable quantile regression analysis confirmed the trends observed at univariable 
analysis, with less marked differences (Table S1). In particular, physician-assessed dysphagia and 
time from RT end were not significant; males had significantly higher median and 3rd quartile 
compared with females (Figure 1A). Positive HPV status had significantly higher 1st and 3rd 
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quartiles compared with HPV negative (Figure 1B). For xerostomia the median and the 3rd quartile 
reached significance; for instance, high grades had significant lower median scores compared with 
lower grades (Figure 1C).  
The interaction between T-stage and  HPV status highlighted above (i.e. HPV negative patients 
having significantly lower MDADI-CS in the T3-4 subset), was confirmed at multivariable quantile 
regression analysis [median MDADI-CS of HPV positive vs negative patients in T3-4 subset: 7 (95% 
CI  1.56-12.44; p=0.012)] (other data not shown).  
Discussion 
Our study suggests that PRO measured by using MDADI questionnaire identified more evident 
swallowing symptoms compared with physician assessment in a population of OPC patients. With 
a median time from treatment end of 30 months, about 18% of patients had “poor” MDADI-CSs 
lower than 60 [16]. However, physicians-assessed dysphagia was recorded as G2 in only 4% of 
patients. We confirmed that observer-based rating of toxicity underestimates the patient-scored 
side effects, measured by QoL questionnaires [26,27]. Therefore, even a moderate dysphagia 
could impact on QoL as reported by Hunter et al. [6] in an OPC population. Similarly, Gluck et al. 
[28] showed that reporting only grades ≥3, the most widespread toxicity criteria in recent trials on 
HNC therapy, may not be the best way to estimate dysphagia burden. 
By evaluating MDADI subscale scores, we observed that emotional and physical scores were the 
poorest, while functional scores were more favorable. This witnesses, as reported in other papers, 
that despite  physical difficulty in swallowing, patients were able to cope with their condition, 
achieving acceptable  functional outcomes [16,29]. It should be recognized, however, that 
psychological and rehabilitative supports should be included in the follow-up program, since 
dysphagia could strongly affect QoL leading to anxiety and depression [30].  
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Dysphagia is strongly related to a substantial number of clinical and treatment-related parameters, 
even if the reported series used different tools to assess dysphagia. Besides PRO questionnaires 
and physician-assessed scales, endoscopic or radiological examination such as the Fiberoptic 
Endoscopic Evaluation of Swallowing (FEES), the videofluoroscopic swallow test (VFSS), or the 
evaluation of presence of NGT or PEG have also been used to assess dysphagia. A recent 
systematic methodological review about swallowing dysfunction after RT-CHT for HNC found two 
risk factors supported by robust evidence, namely the use of RT-CHT and the presence of 
hypopharyngeal carcinoma [31].  
In this specific patient series we also showed that HPV status, xerostomia and gender were 
independent predictors for MDADI-CS at multivariable analysis.  
The favorable prognostic value of HPV status on dysphagia is another important result. Other 
works have suggested a good functional outcome for patients with non-surgically treated HPV 
positive cancers [11,16,32]. However, these results derived from studies with limited samples or 
lack of patient-reported measures. Our study demonstrated that, based on the evaluation of 
reported dysphagia in HNC survivors, HPV was one of the most favorable prognostic factor. This 
fact could reflect an increased tolerance of HPV-related diseases to late effects. On the other side, 
HPV-negative cancers, being more frequently associated with chronic insult of genotoxic agents 
(smoking and alcohol), could be more prone to treatment-related toxicities.  
It is interesting to note the double pattern of toxicities in HPV-related diseases: in the acute phase, 
incidence of mucositis, dysphagia, and opioids use are higher in HPV-positive cancers than in their 
negative counterpart [33,34]; in the late period, however, the rate of toxicities changes in these 2 
groups as showed by our results. HPV-positive microenvironment (richer in effector T cells, 
cytokines and chemokines) may explain the higher level of acute inflammation [35]. 
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Similarly, in the trial by Bonner et al. [36], evaluating RT with or without cetuximab, the analysis of 
OPC patients revealed that in the acute phase patients with p16-positive cancer had a higher 
incidence of G3/4 mucositis and dysphagia compared with those with p16-negative OPC. On the 
other side, at 12 months, the rate of feeding tube dependence was higher for patients with p16-
negative cancers [36].  
Salivary flow is of paramount importance for an efficient swallowing [36-40]. Moreover, 
hyposalivation is associated with changes in the perception of swallow ability and changes in diet 
[41]. Recently, Teguh et al. [42] also found a high correlation between the items of the EORTC 
H&N35 questionnaire regarding swallowing, dry mouth, and sticky saliva. More recently, a 
prospective longitudinal study of 93 patients with OPC treated with definitive IMRT-CHT showed 
that xerostomia significantly contributed to patient-reported dysphagia [43]. Our data confirmed 
this association, with patients who experienced G0-1 xerostomia (reported by the physician) 
having significantly higher MDADI-CS at median and 3rd quartile compared to patients with G2 
toxicities.  
As for gender, to our knowledge it has been never reported that gender independently impacts on 
dysphagia, with males showing better MDADI-CS compared with females. In the group of patients 
with higher values of MDADI-CS (median and 3rd quartile), the differences between males and 
females were significant. Correlation between gender and other domains of QoL has been 
previously published. Teguh et al. [42] found that gender was a significant factor for late dry 
mouth. Besides, at  multivariate analysis, Leung et al. [44] found that gender was an independent 
prognostic factor for QLQ-C30. Thus, it is possible that the impact of gender could be related to 
more interconnected domains of QoL (xerostomia, dysphagia).  
Unlike other Authors, we found no significant association between swallowing dysfunction and 
other factors such as age, and advanced T and N stage [1,45-49], probably because of differences 
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in patients’ characteristics and treatment. We found a different association between HPV and 
MDADI-CS in the two T stage groups: in the T1-2 subset HPV- negative and -positive patients had 
similar MDADI -CS distribution, whereas in the T3-4 subset HPV-negative patients had significantly 
lower MDADI-CS. In a recent two-year longitudinal report by Goepfert et al, on 116 loco-regionally 
advanced OPC survivors treated with IMRT, tumor stage was one of the most important predictors 
of patient-reported swallowing over time, even after assessing for multicollinearity with and 
potential differences in radiation dose by tumor stage [49]. The majority of patients received 
accelerated RT (planned schedule was 6 weeks, with 60 Gy in 33 fractions for T1 disease and 72 Gy 
in 40-42 fractions through concomitant boost regimen) fraction) and split-field IMRT. On the 
contrary, in our study all patients received conventional fractionation (fraction size up to 2.2. Gy) 
and IMRT or VMAT with swallowing sparing when clinically possible. The lack of robust RT dose 
constraints on all swallowing structures, as deduced from the paper by Goepfert et al, could have 
a greater impact on dysphagia in patients with extensive tumors, particularly when accelerated RT 
is employed [49].   
We also found no impact of neck dissection, differing from other series [42]. However, Hutcheson 
et al. [50] showed that post-operative neck surgery did not influence chronic dysphagia rates, 
justifying the inclusion of patients receiving dissection in the present analysis. Use of enteral 
nutrition during treatment resulted in worse dysphagia only in the physical and functional 
subscales. Enteral feeding during the RT course may be associated with long-term tube 
dependence, leading to prolonged inactivity of swallowing muscles and esophageal constriction 
[51,52]. The rate of enteral nutrition need was quite low in our series and most patients adopted a 
reactive enteral strategy, thus with limited time of inactivity of swallowing structures. Indeed, 
better swallowing outcomes are evident when reactive feeding tubes are used in preference to 
prophylactic gastrostomy tubes to supplement enteral nutrition during RT-CHT [53,54]. 
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Considering altogether patients receiving enteral nutrition, regardless of type of feeding tube, we 
disclosed no difference in MDADI-CS scores between patients who received placement of feeding 
tube during treatment and patients who did not. This was likely due to the short duration of 
enteral feeding, although a trend of better scores was found on a univariable analysis among 
patients without enteral nutrition. Differently, in a large retrospective cross-sectional study by 
Hutcheson et al. [22] conducted on 1386 HNC patients, an average gap of 10 points in MDADI-CS 
was identified between feeding tube dependent versus non tube-dependent patients.  The most 
important distinction between our work and that of Hutcheson et al. is that the significant 
MDADI/tube association observed by Hutcheson et al. was based on current feeding tube use at 
the time of MDADI collection, whereas in our study we modeled past feeding tube duration as a 
covariate for MDADI. 
We also reported a favorable impact of longer time from treatment end on patient-reported 
dysphagia, even if only at univariable analysis, with a median CS of 71.5 and 76 in patients 
evaluated at ≤24 and >24 months from the end of RT, respectively. It is known that the effects of 
late radiation-induced toxicity on deglutition and QoL are more severe in the first 6-12 months 
after treatment and gradually decrease after 18 to 24 months [5,55,56]. Caudell et al. [1] showed 
improvement of swallowing dysfunction over time in patients on RT. However, in the previously-
cited paper by Goepfert et al., MDADI scores remained depressed at 24 months compared to 
baseline, suggesting only partial recovery of perceived swallowing function [49]. In a second 
recent paper by Goepfert et al., which aimed at characterizing long-term MDADI results following 
IMRT for patients with “low-intermediate risk” OPC included in current trials (e.g., ECOG 3311, 
NRG HN002, CRUK PATHOS), a poor MDADI CS (<60) was reported in 4%, 11%, 15%, and 9% of 
patients at baseline and 6, 12, and 24 months, respectively [16]. 
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We acknowledge the limitations of our study, primarily the cross-sectional nature of the analysis, 
the different protocols and standard of management across involved Centers, and the limited 
number of patients for outcomes other than MDADI. The lack of a longitudinal MDADI scores 
assessment makes it difficult to assess the transferability of the results. We were not able to 
define the changes in swallowing scores from baseline to follow-up, as baseline assessment 
consisted only in a physician-assessed evaluation. We recognize that the optimal time point for 
dysphagia assessment by PRO is still to be defined, however, the evolution and recovery of 
swallowing disorders suggest that baseline, end of treatment, 3, 6 and 12 months from treatment 
end and then yearly could constitute an useful timeline for assessment of this toxicity, able to 
correct and prevent further deterioration. 
Another important limitation is that we reported only PRO and physician-assessed dysphagia. 
However, penetration/aspiration and biomechanical swallowing disorders cannot be reliably 
judged using questionnaires and self-reports, reinforcing the need for clinical tests of aspiration, 
i.e. videoendoscopic evaluation of swallowing (VEES). A combination of measures is currently 
required to comprehensively report on dysphagia.  
Moreover, we did not study the potential role of smoking status, due to the absence of complete 
data. Interestingly, in the paper by Goepfert et al., current smokers had a 9.4-fold lower mean 
MDADI over time than never smokers [49]. 
In addition, the correlation between dosimetric results and swallowing organs, as well as the 
relationship between oropharyngeal acute mucositis and dysphagia, was not assessed. This latter 
is a crucial point as it has been suggested that inflammation and edema are underlying causes of 
swallowing organs dysfunctions [57].  
Lastly, given the cross-sectional nature of the study, we cannot rule out that non-HPV patients had 
worse pre-therapy scores, thus affecting the observed findings. 
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Conclusions 
MDADI may better describe swallowing symptoms than physician-reported assessment. Overall, 
most patients had good patient-reported dysphagia with the emotional and physical domains as 
the most depressed. Our data confirmed the role of HPV and xerostomia as predictive factors in 
determining dysphagia perception. This underlines the need to better tailor therapy, supportive 
care, and intervention, especially in HPV-negative patients, with the aim of ameliorating their QoL. 
However, prospective studies in a larger population are necessary to either confirm or discard 
these preliminary findings. 
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Figure 1. Results of the multivariable quantile regression model for the three variables significantly 
associated with MDADI-CS.  
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In the vertical axis, Δ represents the MDADI-CS quartiles difference between two categories 
estimated by the model. For instance, in panel A the continuous line joins three points: the 1st one 
is the estimated difference between the MDADI first quartiles in males vs females, i.e. 8.00 (95% 
CI: -1.75 – 17.75, Table 3 first row/first column). Such a difference, being estimated according to a 
multivariable model that takes into account the association between the covariates, is slightly 
lower than the corresponding observed difference (67-55=12, Table 2 first and second rows/last 
column). The 2nd point is the estimated difference between the MDADI medians in males vs 
females (8.00 (2.24 – 13.76), Table 3 first row/second column; observed difference: 76-65=11, 
Table 2). The 3rd point is the estimated difference between the MDADI third quartiles in males vs 
females (11.00 (3.68 – 18.32), Table 3 first row/third column; observed difference: 84.3-73.5=10.8, 
Table 2). The shaded area shows the 95% CI of each difference: CIs not including the zero line 
correspond to 5% significant differences. 
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Table 1: Baseline patient and treatment characteristics. 
 N % 
   
Gender   
Male 112 75.7 
Female 36 24.3 
Age, years   
Median (IQR) 59 (53-64) 
≤55 54 36.5 
56-65 55 37.2 
>65 39 26.3 
T stage†   
T1-T2 83 56.1 
T3-T4 65 43.9 
N stage†   
N0-N1-N2a-N2b 110 74.3 
N2c-N3 38 25.7 
Surgery   
No 128 86.5 
Yes 20 13.5 
Treatment combination   
Concurrent RT_CHT 94 63.5 
I-CHT>RT-CHT 54 36.5 
Pre-therapy HPV status   
Negative 34 23.0 
Positive 98 66.2 
Not defined 16 10.8 
NGT or PEG before i-CHT or RT-CHT   
No 141 95.3 
Yes 7 4.7 
Time of maintenance of enteral feeding,   
days   
No enteral feeding 95 64.2 
PEG before treatment 6 4.1 
Enteral feeding within 30 days 20 13.5 
Enteral feeding beyond 30 days 27 18.2 
Median (IQR) 37 (30 - 59) 
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Table 1 (continue): Baseline patient and treatment characteristics. 
Time from treatment end, months   
Median (IQR) 30 (16 - 50) 
≤24 61 41.2 
>24 87 58.8 
Baseline dysphagia (before i-CHT or RT-   
CHT)   
G0 121 81.7 
G1 22 14.9 
G2 5 3.4 
Late Physician-assessed dysphagia‡   
G0 109 73.6 
G1 33 22.3 
G2 6 4.1 
Late Xerostomia assessed dysphagia‡   
G0 47 32.0 
G1 64 43.5 
G2 36 24.5 
 
CHT: chemotherapy; IQR: interquartile range; NGT: nasogastric 
tube; PEG: percutaneous endoscopic gastrostomy; RT: 
radiotherapy. 
† T and N stage according to AJCC VII edition. 
 
‡ according to CTCAE v4.0 scale and recorded during follow-up 
visit(at least 6 months after RT-CHT) 
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Table 2. M.D. Anderson Dysphagia Inventory score according to patients’ and tumor characteristics and treatments† 
 
 MDADI-G;   MDADI-F   MDADI-P  MDADI-E   MDADI-CS 
                
Gender                
Male 80 (80 - 80); 76.6 (20.6) 80 (72 - 96); 81.5 (15.0) 73 (62.3 - 80); 72.1 (16.5) 77 (67 - 87); 75.6 (12.8) 76 (67 84.3-); 75.6 (13.5) 
Female 80 (40 - 80); 62.2 (28.2) 72 (60 - 81); 71.3 (15.7) 55 (47.3 - 68.5); 58.3 (17.7) 70 (59.3 - 80); 68.8 (17.1) 65 (55 - 73.5); 65.3 (14.9) 
p-value   0.0005   0.0004  0.0134 0.0276   0.0001 
Pre-therapy HPV status                
Negative 80 (60 - 80); 70.6 (24.2) 72 (61 - 83); 72.9 (15.5) 66.5 (50 - 75); 63.3 (18.0) 70 (57.8 - 79.3); 68.9 (12.7) 69 (57 - 77.8); 67.7 (14.4) 
Positive 80 (65 - 80); 74.3 (23.3) 80 (72 - 96); 81.1 (15.3) 71.5 (60 - 80); 71.6 (17.1) 78.5 (70 - 87); 76.3 (14.7) 76 (67 - 84.8); 75.6 (14.1) 
p-value   0.6557   0.0043  0.0379 0.0026   0.0135 
Late Physician-assessed Xerostomia‡                
G0 80 (80 - 100); 78.7 (23.4) 88 (74.0 - 98); 84.6 (15.0) 78 (63 - 89); 75.4 (17.8) 83 (70 - 87); 79.5 (12.1) 80 (70 - 90.5); 79.1 (14.6) 
G1 80 (75 - 80); 74.7 (20.6) 82 (71 - 92); 80.2 (14.5) 70 (60 - 80); 69.0 (17.6) 77 (67 - 83); 74.4 (13.8) 73.5 (66 - 84); 73.7 (13.3) 
G2 80 (40 - 80); 62.8 (25.8) 72 (60 - 80); 70.0 (15.4) 60 (49.5 - 68.5); 60.0 (14.1) 67 (57 - 77); 66.7 (14.1) 64.5 (57.5 - 71.3); 64.5 (12.2) 
p-value   0.0004   <0.0001  <0.0001 <0.0001   <0.0001 
Late Physician-assessed dysphagia‡                
G0 80 (60 - 80); 74.1 (23.3) 80 (72 - 96); 81.2 (15.6) 70 (60 - 80); 70.7 (17.6) 77 (67 - 87); 75.4 (13.0) 76 (65.75 - 84.3); 74.8 (14.5) 
G1 80 (80 - 80); 72.7 (23.4) 72 (60 - 84); 74.8 (15.2) 65 (53 - 75); 65.2 (18.1) 77 (67 - 83); 72.1 (16.9) 69 (64 - 80); 70.2 (13.8) 
G2 60 (40 - 80); 56.7 (26.6) 68 (61 - 72); 64.7 (9.6) 55.5 (48 - 66.8);56.3 (11.3) 61.5 (54.75 - 70.5); 62.7 (12.3) 59 (55 - 62.3); 60.2 (7.3) 
p-value   0.2814   0.0021  <0.0001 0.1105   0.0123 
Enteral nutrition administration                
No 80 (70 - 80); 75.0 (22.8) 80 (72 - 96); 81.4 (15.5) 73 (60 - 80); 71.3 (17.5) 77 (68.5 - 87); 74.9 (14.2) 76 (66 - 84.5); 75.2 (14.2) 
Yes 80 (50 - 80); 71.5 (22.7) 76 (64 - 90); 76.1 (15.4) 65 (51.5 - 75); 64.6 (18.1) 73 (63 - 83); 72.7 (14.9) 71 (59.5 - 80.5); 70.0 (15.0) 
p-value   0.5070   0.0358  0.0339 0.2737   0.0673 
Time from treatment end , months                
≤24 80 (60 - 80); 71.2 (24.1) 76 (64 - 88); 75.5 (14.8) 68 (55 - 75); 65.3 (16.7) 73 (63 - 80); 72.6 (12.9) 71 (61.00 - 78); 70.2 (13.5) 
>24 80 (80- 80); 74.5 (23.0) 84 (72 - 96); 81.4 (16.1) 70 (60 - 85); 71.1 (18.1) 77 (67 - 87); 74.9 (15.1) 76 (65.00 - 86); 75.1 (14.9) 
p-value   0.5844   0.0078  0.0590 0.1924   0.0467  
 
† To descriptively represent the MDADI distribution, each cell shows: the median and interquartile range in parenthesis (data coherent with the results of the 
multivariable quantile regression model), the mean and the standard deviation in parenthesis. MDADI-G: MDADI-Global assessment; MDADI-F: MDADI-functional; 
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MDADI-P. MDADI-Physical; MDADI-E: MDADI-emotional; MDADI-CS: MDADI-composite score; ‡ according to CTCAE v4.0 scale and recorded during follow-up visit (at 
least 6 months after RT-CHT) 
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Table S1. Results of multivariable quantile regression model analyzing the association between the M.D. 
Anderson Dysphagia Inventory composite score (MDADI-CS) and patients’ and tumor characteristics 
and treatments.† 
 
 1st quartile  Median 3rd quartile 
     
Gender     
Male vs Female 8.00 (-1.75 – 17.75) 8.00 (2.24 – 13.76) 11.00 (3.68 – 18.32) 
p–value 0.1071 0.0068 0.0035 
Pre–therapy HPV status     
Positive vs Negative 12.00 (3.57 – 20.43) 5.00 (-1.16 – 11.16) 9.00 (4.28 – 13.72) 
p-value 0.0056 0.1110 0.0002 
Not Defined vs Negative 1.00(14.65 – 16.65) 0.00 (-10.34 – 10.34) -1.00 (-16.41 – 14.41) 
p-value 0.8997 1.000 0.8981 
Late Physician-assessed 
xerostomia‡    
G2 vs G1 or G1 vs G0 -5.00 (-10.09 – 0.09) -6.00 (-9.84 – 2.16) -7.00 (-10.50 – -3.50) 
p-value 0.0539 0.0025 <0.0001 
Late Physician-assessed 
dysphagia‡     
G2 vs G1 or G1 vs G0 -2.0 (-9.22 – 5.22) -1.00 (-5.95 – 3.95) -4.00 (-8.71 – 0.71) 
p-value 0.5848 0.6903 0.0951 
Time from treatment end, months     
>24 vs ≤24 1.00 (-5.89 – 7.89) 2.00 (-3.48 – 7.48) 1.00 (-4.29 – 6.29) 
p-value 0.7745 0.4714 0.7091  
 
† Each cell shows the difference (confidence interval) between the quartiles (1st, median and 3rd) in 
the covariate categories. ‡ The variable was linearly modeled, thus the corresponding regression 
coefficient estimated the difference between the MDADI-CS quartiles for every 1-unit increment (i.e. 
G1 vs G0 or G2 vs G1). 
 
